arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Benitec Biopharma Inc.

BNTC
$13.63 ▲ +0.50 (+3.81%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Benitec Biopharma Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $673.1M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -5.9%
FCF / Share $-0.09
Trailing P/E
Price / Book 2.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-8.96M
↓ -77.2%
FCF / Share Free cash flow per share
$-0.09
↓ -10.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
19
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters